This article is accompanied by an editorial: Perineural dexamethasone e The dilemma of systematic reviews and meta-analyses by Marhofer et al., Br J Anesth 2018:120:201-203, doi: 10.1016/j.bja.2017.015.
There is on-going research to improve strategies of analgesia after surgery. Postoperative pain, in addition to being an unpleasant experience, negatively affects postoperative recovery, can prevent early hospital discharge, and can increase the risk of postoperative complications and the development of chronic pain. 1 Despite progress in pain management, a recent study including more than 115,000 patients showed that the prevalence of severe postoperative pain on the first day after surgery is still high, even after minor surgery. 2 Regional anaesthesia can provide effective pain relief and methods that prolong its effect have obvious appeal. Dexamethasone has been evaluated as an adjunct to regional anaesthesia compared with placebo. 3 Authors of one meta-analysis concluded that perineurally administered dexamethasone does prolong analgesia 4 and authors of another 5 suggested it is associated with a faster onset of analgesia, sensory and motor block. In studies focusing on brachial plexus blocks, it has been suggested that perineural dexamethasone can prolong the duration of analgesia and of motor block. 6 I.V. dexamethasone has also been shown to reduce pain at rest and with movement and opioid consumption after surgery 7 when compared with placebo. To date, it is unclear whether the perineural administration confers advantages over the i.v. administration of this drug. One study found a longer duration of analgesia with i.v. dexamethasone compared with the perineural route 8 while another study 9 came to the opposite conclusion. With the present systematic review, we sought to integrate all the data assessing i.v. compared with perineural dexamethasone administration and its effect on postoperative pain outcomes in patients undergoing surgery under regional or combined regional and general anaesthesia. As there were several studies addressing this question in the public domain, with heterogeneous results, we aimed to conduct a systematic review with a metaanalysis and interpretation that included a thorough assessment of the certainty of the results. We added to the existing knowledge by using a conservative approach to meta-analysis, using a random effects model to account for between-studies heterogeneity and focusing on trials with low risk of bias. By including trial sequential analysis, we include consideration of the required information size for the clinical question that we pose and a more accurate estimate of the risk of random error in the current evidence.
Methods
Our systematic review was registered with PROSPERO, the international prospective register of systematic reviews of the National Institute for Health Research (www.crd.york.ac.uk/ PROSPERO/#index.php, registration number CRD42016036 798). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 10 were followed.
Literature search
We performed a systematic electronic literature search in the databases MEDLINE, Epub, Embase.com (Embase plus MED-LINE), Cochrane Central, Web of Science, and Google Scholar on August 4, 2016 in order to identify trials that compared perineural with i.v. dexamethasone in patients receiving regional anaesthesia. The exact search strategies for the different databases are in Appendix 1.
The program endnote was used to manage the studies identified by the search. After removing duplicate citations, two authors (M.H., M.K.) independently screened the search results for eligible trials. In addition, we searched a clinical trials registry, www.clinicaltrials.gov.
Inclusion and exclusion criteria
We defined inclusion and exclusion criteria a priori.
For inclusion, studies had to have the following characteristics (specified according to the PICO acronym):
Patients: adults undergoing surgery under regional anaesthesia alone or combined with a general anaesthesia;
Intervention: addition of dexamethasone to local anaesthetic for perioperative analgesia (perineural dexamethasone group);
Comparator: i.v. dexamethasone (i.v. dexamethasone group);
Outcomes: Primary outcome -duration of analgesia. Secondary outcomes -duration of sensory block, duration of motor block, onset time of block, pain after surgery, use of peripheral analgesics, opioid consumption, patient satisfaction, all adverse events reported in the trials.
Exclusion criteria were: patient age under 18 yr, studies without randomization.
Data extraction and data collection
Data were extracted by two authors (M.H., M.K.) from the reports that were considered eligible.
We report the primary outcome of each study included into our meta-analysis. The primary outcome was the outcome explicitly mentioned as primary in the text or the variable for which a sample size calculation was done or the variable that was first reported in the results section of the study.
If two or more groups using perineural dexamethasone were studied, these data were combined for meta-analysis. The same was planned for studies applying more than one i.v. dexamethasone dose. Combining dichotomous data was by simple addition; for the combination of continuous data we used the formula published in the Cochrane handbook. 11 We contacted authors of eligible studies to obtain missing original data. Postoperative consumption of morphine equivalents was calculated from other opioids using the website: http:// opioidcalculator.practicalpainmanagement.com/conversion. php. This site does not include piritramide and in case of this opioid, we assumed a relative potency of 0.7 compared with morphine. 12 
Assessment of risks of bias
We used the Cochrane Risk of Bias tool 13 to analyse the methodological quality of the studies; this analysis was done by two authors independently (M.H., M.K.). This tool allows for an assessment of the risks of selection bias (random sequence generation, allocation concealment), performance bias (blinding of participant and personnel), detection bias (blinding of assessor), and attrition bias. When it was unclear if a domain was satisfactory, we contacted the first author of the trial to try to clarify the methodology. In case of disagreement between the two authors (M.H., M.K.), we planned to consult a third author (S.H.) to resolve the disagreement. We considered a trial to be at low risk of bias when there was adequate random sequence generation, adequate allocation concealment and outcome assessment was adequately blinded.
Conventional meta-analysis
We decided a priori to perform meta-analyses when at least three studies with at least 100 patients per treatment arm were identified. We performed meta-analyses including only trials that we had assessed as low risk of bias and presented these results as our principal results. As a sensitivity analysis, we also performed meta-analyses including all eligible trials independent of risk of bias. Review Manager (RevMan, version 5.3) Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014 was used for meta-analysis. We applied the random effects model as clinical and methodological heterogeneity across studies was expected. We calculated risk ratio (RR) and 95% confidence interval (95% CI); the I 2 statistic was used to assess heterogeneity. 14 A P-value of less than 0.05 was taken to indicate statistical significance.
Assessment of publication bias: Contour-enhanced funnel plots
For continuous outcomes, the Cochrane Collaboration recommends using statistical tests for funnel plot asymmetry, but highlights that results should be interpreted cautiously. 15 We therefore performed contour-enhanced funnel plots to consider the risk of publication bias for our primary outcome.
Meta-regression
Random effects meta-regression was performed with the dexa-methasone dose as moderator in order to assess a doseresponse effect. Meta-regression, bubble plots and contourenhanced funnel plots were performed with R version 3.1.3 with the "meta" package (version 4.2-0) and "metaphor" package (version 1.9-7).
Trial-sequential analysis
If a sample size has not been reached in a randomized clinical trial, the threshold for significance needs to be adjusted so that overall risks of type I and type II errors remain below the desired levels. Trial sequential analysis is a statistical approach that applies techniques developed for repeated statistical testing in clinical trials to cumulative meta-analysis. [16] [17] [18] [19] [20] By considering meta-analysis updates as analogous to interim analyses in single trials, monitoring boundaries are used to maintain overall risks of random error at the desired levels. Results are presented as a graph that contains the cumulative Z-curve (the Z test value at each meta-analysis update), the conventional level of significance (e.g., Z score¼1.96 for a P value threshold of 5%, independent of the quantity of evidence that has accumulated), the number of patients in meta-analysis, the estimated required information size, trial sequential significance boundaries, and futility boundaries. The trial sequential significance boundaries are constructed by adjusting the thresholds for significance such that the overall risk of type 1 error is less than the desired level (usually 5%). A cumulative Z curve that is greater than the trial sequential boundary is considered a statistically significant effect. In a single clinical trial, monitoring boundaries depend on the sample size and are therefore true for the assumptions used to calculate that sample size. In a meta-analysis, the required information size is the equivalent of the sample size and the results of the trial sequential analysis are therefore also dependent on the assumptions used to estimate the required information size.
We performed trial sequential analysis on the primary outcome including trials we assessed as low risk of bias. 16e20 We calculated RIS allowing for type 1 error of 0.05, and type 2 error of 0.20, mean difference from the effect estimate from the conventional random effects model, and estimated variance and heterogeneity from that present in the included trials. 14 We constructed trial sequential analysis boundaries based on the O'Brien-Fleming alpha-spending function. We used trial sequential analysis software (version 0.9 Copenhagen Trial Unit, Copenhagen, Denmark) to perform this analysis.
Grading of recommendations assessment, development, and evaluation system (GRADE)
We used GRADE 21 to rate the quality of evidence and strength of recommendation of our primary outcome. The following criteria were judged:
1. Risk of bias: risk for bias in the included trials as assessed above; 2. Inconsistency: I 2 statistic was 50% or higher without satisfactory explanation by subgroup analysis/meta-regression; 3. Indirectness: outcome data were based on indirect comparisons of interest, on the population of interest, and on the outcome of interest (surrogate markers); 4. Imprecision: studies include relatively few patients and/or events, the total number of participants did not exceed the required information size and did not cross an appropriate threshold for significance or futility when applying trial sequential analysis; 5. Publication bias: asymmetry of the contour-enhanced funnel plot.
When one of the above items was assessed as a risk, the evidence was down-graded by two levels (very serious risk) or one level (serious risk). We used the following interpretations of this assessment of quality of evidence for our primary outcome:
High quality: Further research is very unlikely to alter the confidence in the estimate of the effect; Moderate quality: Further research is likely to alter the confidence in the estimate of the effect; Low quality: Further research is very likely to alter the confidence in the estimate of the effect; Very low quality: The confidence in the effect estimate is very little. Figure 1 shows the flow chart of our study selection. Of the 1648 studies retrieved, 10 were potentially eligible to be included and were subjected to an assessment of the methodological quality. 8, 9, [22] [23] [24] [25] [26] [27] [28] [29] Study characteristics Table 1 contains the details of the included studies. In all studies, long-acting local anaesthetics were used. Table 2 provides exact definitions of the outcomes analysed in the included studies.
Results

Study selection
Risk of bias within studies
The methodological quality of the studies is given in Figure 2 . We assessed 10 of these trials as low risk of bias, according to our pre-specified criteria. 8, 9, [22] [23] [24] [25] [26] [27] [28] [29] In our review, there were no disagreements between the authors and the consultation of a third author was not required.
Synthesis of results
Primary outcome:duration of analgesia Figure 3 shows the conventional meta-analysis for the primary outcome including nine trials that had data for this outcome. 8, 9, [22] [23] [24] [26] [27] [28] [29] when comparing perineural with systemic dexamethasone, the estimated duration of analgesia was 241 min longer in the perineural group. Using a conventional threshold for the significance, the 95% confidence interval (CI) was 87 to 394 min.
Secondary outcomes
Duration of sensory block: Five studies reported on this variable. 8, 25, 26, 28, 29 In Supplementary Figure S1 , the meta-analysis is shown. When comparing perineural with systemic dexamethasone, the estimated duration of sensory block was 139 min longer in the perineural group. Using a conventional threshold for the significance, the 95% CI was 19 to 259 min.
Duration of motor block:
This outcome was reported in four studies. 23, 26, 28, 29 When comparing perineural with systemic 24 The time between the end of the operation and the first request of analgesics by the patient.
The pain relief satisfaction score of patients was evaluated using a 3-point scale (0¼unsatisfied, l¼uncertain, 2¼satisfied) at 48h. The period between the end of injection and loss of sensation to pinprick
Continued
Continued dexamethasone, the estimated duration of motor block was 235 min longer in the perineural group. Using a conventional threshold for the significance, the 95% CI was 85 to 384 min. Supplementary Figure S2 .
Onset time of block: This outcome was reported in two studies and a meta-analysis was not performed. One study 26 reported the onset time of the motor block and a statistically significant difference was not observed between the group receiving i.v. and the group receiving perineural dexamethasone. In another study, 9 the time to complete block did not differ between the i.v. and the perineural dexamethasone groups.
Pain after surgery and use of peripheral analgesics: Pain was reported in seven studies. 8, 9, [22] [23] [24] [25] 27 Different pain scales and different time-points prevented us from synthesizing the data in a meta-analysis. Supplementary Table S1 gives details of the individual studies. One study 27 found a significantly higher pain score 24 and 48 h after surgery in the i.v. group. Desmet and colleagues 22 reported higher values 48 h after surgery in the perineural group. Five studies 8,9,23-25 did not find a significant difference. The use of non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol was described in three trials, 22, 24, 25 with no significant difference between the two treatment arms.
Opioid consumption: In response to our request we obtained piritramide data from Desmet and colleagues 22 : One patient from the perineural and three patients from the i.v. group received each 15 mg piritramide i.m. in the first 24 postoperative h. Based on these data we calculated mean and standard deviation of morphine equivalents. Opioid consumption in the first 24 h was reported by six studies. 8, 9, 22, 23, 25, 27 The mean difference between the two administration routes was not statistically significant ( Supplementary Fig. S3 ).
The number of patients requiring opioids was assessed in one study. 24 This number was significantly higher in the i.v. us perineural groups after 24 h, but no longer after 48 h.
24
Patient satisfaction: Patient satisfaction was evaluated in six studies 8, 9, [22] [23] [24] 27 (Supplementary Table S2 ). However, the definition of satisfaction used (with surgical anaesthesia, with pain relief, in general), the time points of evaluation (after 24h, after 48h, "in general") and the scores applied (VRS 0-10, VRS 0-2, yes/no) were heterogeneous. In four studies 8, 9, 22, 23 there were no significant differences in patient satisfaction between the groups. Two studies 24, 27 suggested a higher satisfaction with perineural administration. Block success rate: Success of block was reported in four studies. 22, 26, 27, 29 Block was successful in 208 out of 226 patients in the i.v. group us 211 out of 226 patients in the perineural group. This difference was not statistically significant.
Adverse events: There was no significant difference with regard to hoarseness, assessed in three studies 8, 22, 24 or dizziness, reported in two trials 8, 24 (data not shown). Two trials presented data on the incidence of Horneis syndrome; 22, 24 there was no statistical difference for either outcome (data not shown).
Outcome variables that were reported in only one study or that were too different in definition or time of assessment to be combined are shown in Supplementary Table S3 .
Contour-enhanced funnel plots
The contour-enhanced funnel plot for the analysis of duration of analgesia is shown in Supplementary Figure S4 . The plot is asymmetric and is compatible with publication bias.
Meta-regression
We analysed the duration of analgesia for a dose-response effect of dexamethasone. Meta-regression showed no statistically significant association between dosage and duration of analgesia (Fig. 4) . The slope coefficient (s.e.) was 41.7 (48.4), P¼0.389.
Trial-sequential analysis
Trial sequential analysis was applied for the primary outcome, duration of analgesia. As with the conventional meta-analysis, we included all trials that we assessed as low risk of bias. Alongside crossing the conventional boundary for statistical significance (as described above), the cumulative Z-curve (blue line) crossed both the trial sequential monitoring boundary and the required information size (Fig. 5) , indicating that the meta-analysis was sufficiently powered to answer the clinical question defined by the assumptions used. The adjusted 95% CI for the effect size (241 min) was 78 to 403 min.
Grade
We assigned the GRADE level of "low quality" to our primary outcome "duration of analgesia". This assessment was based on the inconsistency in the results, demonstrated with a high I2, and on the risk of publication bias, as a result of asymmetry of the contour-enhanced funnel plot. There was, The blue line represents the summary of what has been found after each trial, the Z score resulting from the cumulative evidence. The curved red lines are the TSA monitoring boundaries, for benefit (on the top of the graph), harm (on the bottom of the graph) and futility (the inner wedge). The horizontal red lines represent a conventional, constant threshold for significance at a z value of 1.96. The RIS is the required information size, which is an estimate of the number of participants required to answer the defined question. The calculation of the RIS depends on the assumptions defined in the methods section (as with a sample size calculation for a single trial) and also incorporates an estimate for heterogeneity. This graph shows that the evidence for this meta-analysis crosses the trial sequential analysis monitoring boundary before it reached the required information size and then went on to pass the required information size itself. We can therefore conclude with reasonable certainty that perineural dexamethasone does provide a longer duration of analgesia than i.v. dexamethasone.
in our assessment, no increased risk from the remaining 3 GRADE criteria: risk of bias, precision and indirectness. We only included trials that we had assessed as low risk of bias, trial sequential analysis demonstrated good precision for the effect size estimate, and the included studies matched the PICO well. As a result of our assessment of inconsistency and risk of publication bias, we down-graded the level of evidence twice, resulting in our assessment of it being "low quality".
Discussion
Using conventional meta-analysis, the primary outcome of our analysis, the duration of analgesia, was 241 min longer when perineural dexamethasone was used compared with i.v. dexamethasone; this was statistically significant. This statistical significance was also seen for this primary outcome when trial-sequential analysis was used. Meta-regression did not find a dose-responsiveness for the duration of analgesia. A contour-enhanced funnel plot for our primary outcome was compatible with publication bias. The GRADE level of "low quality" was assigned to this primary outcome.
We also observed a significantly longer duration of sensory (139 min) and motor block (236 min) with perineural dexametha-sone. There was no difference for opioid consumption in the first 24 h between the perineural and i.v. arms.
Another systematic review, 30 published recently, also assessed our primary question using meta-analysis. While our meta-analyses included 10 studies, Chong and colleagues 30 included 11 studies. The extra data came from a trial by Kawanishi and col-leagues 31 In our systematic review, we included only trials that we assessed as low risk of bias and excluded the data from Kawansihi and colleagues 31 as this trial did not fulfil our criteria for adequate blinding. Despite the differences in inclusion, both meta-analyses did find similar results for our primary comparison: a significantly prolonged duration of analgesia with perineural dexamethasone compared with i.v. dexamethasone (241 min in our study and 226 min in the study by Chong and colleagues). 30 In our systematic review, we included further analyses in order to better examine the certainty of the findings. To assess for adequacy of power and the risk of random error in the setting of sparse data and potential repeated updates, we included trial sequential analysis. The findings from trial sequential analysis, for the assumptions used, showed that the risk of type 1 error was less than 5%. We also performed an assessment of dose-response of perineural dexamethasone on the duration of analgesia and used GRADE to assess more completely the quality of evidence, and the confidence we can have in the result.
There were limitations in our review. Firstly, a contourenhanced funnel plot of our primary outcome was compatible with the presence of publication bias. Secondly, metaregression did not reveal a dose-response relationship. Thirdly, the GRADE level that we assigned to our study was only low quality advising caution for the conclusions. Consequently, even with convincing precision in our meta-analysis, we concluded that the quality of the evidence was low. This conclusion was based on our GRADE assessment, resulting from inconsistency and risk of publication bias. Assessment of risk of publication bias is difficult. We know that publication bias is common in anaesthesia research 32 and that statistical tests for funnel plot asymmetry are useful when the outcome is numerical. Given these factors, and the results of our contour analysis, we decided that the risk of publication bias for this clinical question was meaningful.
The suggestion that perineural dexamethasone may confer benefit was originally made after a meta-analysis that compared perineural dexamethasone to a control without dexamethasone. 5, 6 Choi and colleagues 6 studied brachial plexus block and found a significantly prolonged duration of analgesia with perineural dexamethasone. This effect was more pronounced in the patients receiving a long-acting local anaesthetic. In the meta-analysis by Huynh and colleagues 5 dexamethasone was also found to significantly prolong the duration of motor block and to reduce the onset times of motor and sensory block. These meta-analyses demonstrated that dexamethasone is associated with prolonged analgesia after regional blocks. If dexamethasone does confer meaningful benefit, the next important question is: does it have to be given perineurally, with the associated potential risk of this route, or would i.v. administration have a similar effect? Dexamethasone has no approval for perineural use by the regulatory authorities in Europe or the US. After drugs such as midazolam 33 and ketamine 34, 35 were given spinally and then found to be neurotoxic, several authors have warned against the uncritical epidural, intrathecal, and perineural off-label use of agents and imposed strict requirements for such offlabel studies in humans. 36, 37 Our meta-analysis demonstrates evidence for efficacy of perineural dexamethasone when compared with i.v. dexamethasone. However, uncertainty about this efficacy does remain, because of the lack of a dose-response relationship and the low quality of evidence when using GRADE to assess it. Given the potential for adverse neural effects, and the need for critical appraisal of efficacy and adverse effects before use, further consideration and research is required before dexamethasone is routinely used as a perineural adjunct.
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